Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
2022/09/05 by Friederike Holze, Peter Gasser, Felix Müller +2 · 37 citations
Psychology · Neuroscience · Agricultural and Biological Sciences · #Psychedelics and Drug Studies #Pain Management and Placebo Effect #Plant and fungal interactions
paper · pdf · doi:10.1016/j.biopsych.2022.08.025
Abstract
BACKGROUND: This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness. METHODS: The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period. The primary end point was anxiety symptoms 16 weeks after the last treatment session, assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients. Further outcome measures included ratings for depression symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale, 21-item version) and ratings for acute subjective drug effects. The outcomes for the first period (between-subjects analysis) are primarily shown due to carryover effects. RESULTS: LSD treatment resulted in significant reductions of State-Trait Anxiety Inventory-Global scores up to 16 weeks after treatment (least-square mean [standard error] change from baseline difference = -16.2 [5.8], 95% CI, -27.8 to -4.5, d = -1.18, p = .007). Similar effects were observed for ratings of comorbid depression on the Hamilton Depression Rating Scale, 21-item version (-7.0 [1.9], 95% CI, -10.8 to -3.2, d = -1.1, p = .0004) and the Beck Depression Inventory (-6.1 [2.6], 95% CI, -11.4 to -0.9, d = -0.72, p = .02). Positive acute subjective drug effects and mystical-type experiences correlated with the long-term reductions in anxiety symptoms. Transient, mild, acute untoward effects of LSD treatment were reported by 8 patients (19%). One treatment-related serious adverse event (acute transient anxiety) occurred (2%). CONCLUSIONS: LSD produced long-lasting and notable reductions in anxiety and comorbid depression symptoms up to 16 weeks.
Citations
Cited by
- Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges
- Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
- LSD microdosing in major depressive disorder: results from an open-label trial
- Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
- The ABCs of psychedelics: a preclinical roadmap for drug discovery
- Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
- The role of self-transcendent emotions in psychedelic experiences: a two-process proposal
- Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co‐Use: Results From the European Web Survey on Drugs
- A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations
- Chaplains in Psychedelic Assisted Therapy: Rationale and Competencies
- The science of psychedelic medicine
- Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials
- Psychedelics: preclinical insights provide directions for future research. [europepmc]
- Dose-response relationships of LSD-induced subjective experiences in humans. [europepmc]
- The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. [europepmc]
- Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. [europepmc]
- The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing. [europepmc]
- Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. [europepmc]
- Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. [europepmc]
- The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice. [europepmc]
- The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. [europepmc]
- Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. [europepmc]
- Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. [europepmc]
- Greater subjective effects of a low dose of LSD in participants with depressed mood. [europepmc]
- Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. [europepmc]
- Magnesium-ibogaine therapy in veterans with traumatic brain injuries. [europepmc]
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. [europepmc]
- Effects of DMT on mental health outcomes in healthy volunteers. [europepmc]
- Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics? [europepmc]
- LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. [europepmc]
- Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. [europepmc]
- Epigenetic mechanisms of rapid-acting antidepressants. [europepmc]
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. [europepmc]
- Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. [europepmc]
- Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry. [europepmc]
- A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions. [europepmc]
- The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item. [europepmc]
Related